Abstracts Archive - Page 2384 of 2605 - ACR Meeting Abstracts

Abstract Number: 702 • 2013 ACR/ARHP Annual Meeting
Prediction Of Worsening Of Skin Fibrosis In Patients With Diffuse Systemic Sclerosis Using The EULAR Scleroderma Trials and Research (EUSTAR) Registry
Britta Maurer¹, Nicole Graf², Beat A. Michel³, Carola Metzig⁴, Vivian Lanius⁴, Dinesh Khanna⁵ and Oliver Distler¹, ¹Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²graf biostatistics, Winterthur, Switzerland, ³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Bayer Pharma AG, Berlin, Germany, ⁵University of Michigan Health System, Ann Arbor, MI
Background/Purpose: To identify predictive parameters for the progression of skin fibrosis in patients with diffuse cutaneous SSc (dcSSc) to enable 1) risk-stratification in clinical practice…
Abstract Number: 703 • 2013 ACR/ARHP Annual Meeting
Correlation Between Patient Self-Report Of Symptoms Of Raynaud’s Phenomenon and Objective Assessment Of Digital Microvascular Perfusion Using Infrared Thermography
Marina Scolnik^1,2, Bhavisha Vasta², Darren Hart², Jacqueline A. Shipley², Sue Brown², Eleanor Korendowych², Neil J McHugh^2,3 and John D. Pauling^2,3, ¹Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: Patient self-report of digital colour changes form the basis of a clinical diagnosis of Raynaud's phenomenon (RP) and help classify patients with early systemic…
Abstract Number: 704 • 2013 ACR/ARHP Annual Meeting
Evaluating The Effects Of Combination Aspirin and Dipyridamole (asasantin retard) On Platelet Function, Oxidative Stress and Peripheral Vascular Function In Primary Raynaud’s Phenomenon and Systemic Sclerosis
John D. Pauling¹, Jacqueline A. Shipley¹, Darren Hart¹, Ginger L. Milne² and Neil J McHugh^1,3, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, ³Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: There is evidence of enhanced platelet activation in Raynaud’s phenomenon (RP), particularly in systemic sclerosis (SSc). Upon activation, platelets release vasoconstrictive mediators (e.g. thromboxane…
Abstract Number: 705 • 2013 ACR/ARHP Annual Meeting
Treatment With Rituximab Reduces Activation Of Scleroderma Dermal Fibroblasts
Paolo Fraticelli¹, Salvatore De Vita², Nicoletta Franzolini³, Silvia Svegliati⁴, Cecilia Tonnini⁴, Barbara Gabrielli⁵, Cathryn Anne Scott⁶, Giovanni Pomponio⁷, Gianluca Moroncini⁴ and Armando Gabrielli⁴, ¹Istituto di Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, ²Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ³Presidio Ospedaliero di San Daniele del Friuli, ASS 4 “Medio Friuli, Udine, Italy, ⁴Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy, ⁵Università Politecnica delle Marche, Ancona, Italy, ⁶Department of Medical and Biological Sciences, Università degli studi di Udine ·, Udine, Italy, ⁷Medicina Interna, Ospedali Riuniti, Ancona, Italy
Background/Purpose: There is evidence that B lymphocytes play a role in the pathogenesis of systemic sclerosis (scleroderma). Stimulatory autoantibodies targeting PDGF receptor and activating normal…
Abstract Number: 706 • 2013 ACR/ARHP Annual Meeting
Effect Of Aminaftone On Raynaud’s Phenomenon Secondary To Systemic Sclerosis: A Double-Blind Prospective, Randomized, Placebo-Controlled Pilot Study
Alessandro Santaniello¹, Barbara Vigone², Monica Caronni² and Lorenzo Beretta³, ¹Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ³Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy
Background/Purpose: Raynaud’s phenomenon (RP) is a pivotal manifestation of systemic sclerosis (SSc) which reflects an underlying vasculopathy. Endothelial activation with increased circulating levels of Endothelin-1…
Abstract Number: 663 • 2013 ACR/ARHP Annual Meeting
Propylthiouracil Attenuates Aortic Vasculopathy In An Animal Model Of Systemic Sclerosis
Gianluca Bagnato¹, Alessandra Bitto², Gabriele Pizzino², Neal Roberts³, Domenica Altavilla², Francesco Squadrito², Gianfilippo Bagnato¹ and Antonino Saitta⁴, ¹Rheumatology, University of Messina, Messina, Italy, ²Pharmacology, University of Messina, Messina, Italy, ³University of Louisville, Louisville, KY, ⁴Internal Medicine, University of Messina, Messina, Italy
Background/Purpose: Systemic sclerosis (SSc) is a generalized connective tissue disorder of unknown etiology characterized by thickening and fibrosis of the skin and distinctive visceral involvement…
Abstract Number: 664 • 2013 ACR/ARHP Annual Meeting
Formate, Acetate and Acetone : News Biomarkers in Systemic Sclerosis identified by Metabolomics
Emmanuel Chatelus¹, Francois Marie Moussallieh², Christelle Sordet¹, Arnaud Theulin¹, Alain Meyer¹, Karim El Bayed³, Jean Francois Kleinmann¹, Jean Sibilia¹, Jacques-Eric Gottenberg⁴ and Izzie Jacques Namer², ¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Nuclear Medicine, Strasbourg University Hospital, Strasbourg, France, ³UMR 7177 CNRS/Strasbourg University, Strasbourg, France, ⁴Strasbourg University Hospital, Strasbourg, France
Background/Purpose: High throughput study of metabolic pathways might help identify new biomarkers and therapeutic targets in autoimmune diseases. Systemic sclerosis (SSc) currently lacks prognostic biomarkers…
Abstract Number: 665 • 2013 ACR/ARHP Annual Meeting
DNA hypermethylation of Forkhead box protein 3 (FOXP3) locus leads to quantitative defects of regulatory T cells in systemic sclerosis
Yaoyao Wang¹, Ye Shu², Qing Wang¹, Ming Zhao¹, Gongping Liang¹, Qianjin Lu¹ and Rong Xiao¹, ¹Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China, ²Department of Dermatology, Hunan Children's Hospital, Changsha, China

Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease of which the etiology and pathogenesis remains complex and poorly understood. Attention has recently been directed…
Abstract Number: 666 • 2013 ACR/ARHP Annual Meeting
Involvement Of TCR Vdelta1⁺ NKT Cells In Systemic Sclerosis: Association With Interstitial Pneumonia
Seiji Segawa¹, Daisuke Goto², Masanobu Horikoshi², Yuya Kondo³, Naoto Umeda², Shinya Hagiwara², Masahiro Yokosawa⁴, Tomoya Hirota³, Haruka Miki¹, Hiroto Tsuboi³, Hiroshi Ogishima², Takeshi Suzuki⁴, Isao Matsumoto⁵ and Takayuki Sumida³, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan, ²Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba City, Japan, ³Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁴Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, ⁵Department of Internal Medicine, Faculty of Medicine,, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Interstitial pneumonia (IP) is one of the critical complications in patients with several autoimmune diseases. However, the exact mechanism of IP remains elusive. Recently,…
Abstract Number: 667 • 2013 ACR/ARHP Annual Meeting
IL6 and CCL2 Co-Regulate Fibroblast Dependent Trans-Endothelial Migration Of Mononuclear Cells and Fibrotic Response In Scleroderma
Rebecca Alade¹, Korsa Khan², Xu Shiwen³, Christopher P. Denton⁴ and Voon Ong⁵, ¹Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School, London, United Kingdom, ²Centre for Rheumatology and Connective Tissue Diseases, UCL medical School, London, United Kingdom, ³Rheumatology, Royal Free Hospital, London, United Kingdom, ⁴Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ⁵Department of Rheumatology, UCL Medical School, London, England
Background/Purpose: IL6 is a key mediator recently implicated in activation of extracellular matrix (ECM) proteins in scleroderma (SSc) fibroblasts. CCL2 is a proinflammatory chemokine that…
Abstract Number: 668 • 2013 ACR/ARHP Annual Meeting
Enhanced Expression Of The Cold-Sensing Receptor-TRPM8 In Scleroderma Endothelial Cells and Skin and Endothelial Dysfunction Following TRPM8 Activation
Yongqing Wang¹, David R. Giovannucci² and Bashar Kahaleh³, ¹Medicine, University of Toledo, Toledo, OH, ²Neurosciences, University of Toledo, Toledo, OH, ³Medicine/Rheumatology, University of Toledo, Toledo, OH
Background/Purpose: Cold exposure induces vasospasm and incites reperfusion injury in SSc. The mechanisms responsible for enhanced cold sensitivity in SSc are poorly understood. Transient receptor…
Abstract Number: 669 • 2013 ACR/ARHP Annual Meeting
Up-Regulated Expression Of CXCL5 In Circulating Platelets From Patients With Systemic Sclerosis: A Role In Fibrosis
Hidekata Yasuoka¹, Ken Stern², Yuka Okazaki³, Tetsuya Nishimoto⁴, Tsutomu Takeuchi¹ and Masataka Kuwana¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁴Department of Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic sclerosis (SSc) is a systemic fibroproliferative disease characterized by concomitant occurrence of microvascular injury and autoantibody production. It has long been suggested that…
Abstract Number: 671 • 2013 ACR/ARHP Annual Meeting
Autoantibody Diversity In Scleroderma Patients With Antinucleolar Antibodies and Negative For Three Major Disease-Specific Markers
Sarada Nandiwada¹, Troy Jaskowski², Maureen D. Mayes³, Minoru Satoh⁴ and Anne E. Tebo¹, ¹Pathology, University of Utah, Salt Lake City, UT, ²ARUP Laboratories, Salt Lake City, UT, ³University of Texas Health Science Center at Houston, Houston, TX, ⁴Medicine, University of Florida, Gainesville, FL
Background/Purpose: Antinuclear antibodies (ANA) in a nucleolar pattern (antinucleolar antibodies, ANoA) by indirect immunofluorescence technique correlate with several autoantibody specificities and clinical manifestations in scleroderma…
Abstract Number: 672 • 2013 ACR/ARHP Annual Meeting
Anti-Th/To Antibodies In Various Systemic Rheumatic Diseases Screened By Anti-Rpp25 ELISA
Ann D. Chauffe¹, Eric S. Sobel², Michael R. Bubb¹, Westley H. Reeves³, Michael Mahler⁴, Cristina Gascon⁵, Jason Y.F. Chan¹, S. John Calise⁶, Edward K.L. Chan⁶ and Minoru Satoh¹, ¹Medicine, University of Florida, Gainesville, FL, ²Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, ³Rheumatology & Clinical Imm, University of Florida, Gainesville, FL, ⁴Research, INOVA Diagnostics, San Diego, CA, ⁵Research, INOVA Diagnostics, Inc., San Diego, CA, ⁶Oral Biology, University of Florida, Gainesville, FL
Background/Purpose: Anti-Th/To antibodies (anti-Th) are one of the specificities that show nucleolar staining in indirect immunofluorescence antinuclear antibody test. Anti-Th is associated with systemic sclerosis…
Abstract Number: 674 • 2013 ACR/ARHP Annual Meeting
Systemic Sclerosis Disease Subset Is a Better Predictor Of Long Term Outcome Than Autoantibody Profile
Svetlana I. Nihtyanova¹, Voon H. Ong² and Christopher P. Denton³, ¹Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ²Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, ³Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom
Background/Purpose: Disease subset has been shown to strongly correlate with survival and risk of organ complications in patients with systemic sclerosis (SSc). Nevertheless evidence in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].